Alterations to the blood-retinal barrier in diabetes: Cytokines and reactive oxygen species

Antioxidants and Redox Signaling

Volumn 15, Issue 5, 2011, Pages 1271-1284

  Frey, Tiffany ^a   Antonetti, David A ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOKINE; GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; POLYOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STEROID; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; XANTHINE OXIDASE;

BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; HUMAN; METABOLIC DISORDER; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TIGHT JUNCTION;

ANIMALS; BLOOD-RETINAL BARRIER; CYTOKINES; DIABETIC RETINOPATHY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; REACTIVE OXYGEN SPECIES;

EID: 79960772833     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.3906     Document Type: Review

References (123)

1. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 108: 1234-1244, 1990.
2. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, and Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450, 1994. (Pubitemid 24307211)
3. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampei HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, and King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487, 1994. (Pubitemid 24356306)
4. Al-Shabrawey M, Bartoli M, El-Remessy AB, Ma G, Matragoon S, Lemtalsi T, Caldwell RW, and Caldwell RB. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 49: 3231-3238, 2008.
5. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, Parpia AK, Liou G, and Caldwell RB. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 49: 3239-3244, 2008.
6. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, and Simpson IA. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes 55: 2401-2411, 2006. (Pubitemid 44871140)
7. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, and Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274: 23463-23467, 1999.
8. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, and Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47: 1953-1959, 1998. (Pubitemid 28549205)
9. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, and Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52: 506-511, 2003. (Pubitemid 36173210)
10. Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, and Antonetti DA. TNF-a signals through PKCf/NF-jB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 59: 2872-2882, 2010.
11. Barber AJ, Antonetti DA, and Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 41: 3561-3568, 2000.
12. Barber AJ and Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci 44: 5410-5416, 2003. (Pubitemid 37475417)
13. Barnett PA, Gonzalez RG, Chylack LT, Jr., and Cheng HM. The effect of oxidation on sorbitol pathway kinetics. Diabetes 35: 426-432, 1986. (Pubitemid 16078454)
14. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, and Adamis AP. Integrinmediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41: 1153-1158, 2000. (Pubitemid 30187554)
15. Bazzoni G. Pathobiology of junctional adhesion molecules. Antioxid Redox Signal 15: 1221-1234, 2011.
16. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, and Graves DT. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 172: 1411-1418, 2008. (Pubitemid 351671553)
17. Berry CE and Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555(Pt 3):589-606, 2004. (Pubitemid 38404582)
18. Blasig IE, Bellmann C, Cording J, del Vecchio G, Zwanziger D, Huber O, and Haseloff RF. Occludin protein family: oxidative stress and reducing conditions. Antioxid Redox Signal 15: 1195-1219, 2011.
19. Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, and Bouck N. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 46: 394-400, 2003. (Pubitemid 36547595)
20. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001. (Pubitemid 34000785)
21. Busik JV, Mohr S and Grant MB. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes 57: 1952-1965, 2008.
22. Chakrabarti S and Sima AA. Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. Diabetes 38: 1181-1186, 1989. (Pubitemid 19250406)
23. Chang YS, Munn LL, Hillsley MV, Dull RO, Yuan J, Lakshminarayanan S, Gardner TW, Jain RK, and Tarbell JM. Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties. Microvasc Res 59: 265-277, 2000. (Pubitemid 30140301)
24. Chen P, Guo AM, Edwards PA, Trick G, and Scicli AG. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 293: R1619-1629, 2007. (Pubitemid 47535780)
25. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, and Chung SK. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54: 3119-3125, 2005. (Pubitemid 43334364)
26. Coisne C and Engelhardt B. Tight junctions in brain barriers during CNS inflammation. Antioxid Redox Signal 15: 1285-1303, 2011.
27. Cui Y, Xu X, Bi H, Zhu Q, Wu J, Xia X, Qiushi R, and Ho PC. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 83: 807-816, 2006. (Pubitemid 44308613)
28. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, and Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 53: 2404-2411, 2004. (Pubitemid 39145596)
29. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, and Bouck NP. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 285: 245-248, 1999. (Pubitemid 29329995)
30. DeMaio L, Antonetti DA, Scaduto RC, Jr., Gardner TW, and Tarbell JM. VEGF increases paracellular transport without altering the solvent-drag reflection coefficient. Microvasc Res 68: 295-302, 2004. (Pubitemid 40288126)
31. Demircan N, Safran BG, Soylu M, Ozcan AA, and Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 20: 1366-1369, 2006. (Pubitemid 44921137)
32. Diederen RM, Starnes CA, Berkowitz BA, and Winkler BS. Reexamining the hyperglycemic pseudohypoxia hypothesis of diabetic oculopathy. Invest Ophthalmol Vis Sci 47: 2726-2731, 2006. (Pubitemid 351639862)
33. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, and Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-1348, 2001. (Pubitemid 33107762)
34. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, and Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97: 12222-12226, 2000.
35. Du Y, Smith MA, Miller CM, and Kern TS. Diabetesinduced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 80: 771-779, 2002. (Pubitemid 34809229)
36. Duh EJ. (Ed). Diabetic Retinopathy. Totowa, NJ: Humana Press, 2008.
37. Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, Gehlbach P, Melia M, Pieramici D, Harlan JB, Campochiaro PA, and Zack DJ. Vitreous levels of pigment epitheliumderived factor and vascular endothelial growth factor: Im-plications for ocular angiogenesis. Am J Ophthalmol 137: 668-674, 2004. (Pubitemid 38446681)
38. Dvornik E, Simard-Duquesne N, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, Varma SD, and Merola LO. Polyol accumulation in galactosemic and diabetic rats: Control by an aldose reductase inhibitor. Science 182: 1146-1148, 1973.
39. El-Remessy AB, Abou-Mohamed G, Caldwell RW, and Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: Role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44: 3135-3143, 2003. (Pubitemid 36759784)
40. El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M, Behzadian MA, Ghaly N, Tsai N, Motamed K, and Caldwell RB. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells. FASEB J 21: 2528-2539, 2007. (Pubitemid 47230682)
41. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, and Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162: 1995-2004, 2003. (Pubitemid 36613056)
42. El-Remessy AB, Bartoli M, Platt DH, Fulton D, and Caldwell RB. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 118: 243-252, 2005. (Pubitemid 40277119)
43. Ellis EA, Grant MB, Murray FT, Wachowski MB, Guberski DL, Kubilis PS, and Lutty GA. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 24: 111-120, 1998. (Pubitemid 28006442)
44. Ellis EA, Guberski DL, Somogyi-Mann M, and Grant MB. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 28: 91-101, 2000. (Pubitemid 30045577)
45. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, and Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077, 2010.
46. Erickson KK, Sundstrom JM, and Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 10: 103-117, 2007. (Pubitemid 46440630)
47. Frey RS, Ushio-Fukai M, and Malik AB. NADPH oxidasedependent signaling in endothelial cells: Role in physiology and pathophysiology. Antioxid Redox Signal 11: 791-810, 2009.
48. Gao L and Mann GE. Vascular NAD(P)H oxidase activation in diabetes: A double-edged sword in redox signalling. Cardiovasc Res 82: 9-20, 2009.
49. Gardner TW and Antonetti DA. Novel potential mechanisms for diabetic macular edema: Leveraging new investigational approaches. Curr Diab Rep 8: 263-269, 2008.
50. Gardner TW, Larsen M, Girach A, and Zhi X. Diabetic macular oedema and visual loss: relationship to location, severity and duration. Acta Ophthalmol 87: 709-713, 2009.
51. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, and Grosu P. Expression of acute-phase response proteins in retinal Mü ller cells in diabetes. Invest Ophthalmol Vis Sci 46: 349-357, 2005. (Pubitemid 40041218)
52. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, and Allen H. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386: 619-623, 1997. (Pubitemid 27175429)
53. Giardino I, Edelstein D, and Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 97: 1422-1428, 1996. (Pubitemid 26097031)
54. Gonzalez-Mariscal L, Betanzos A, Nava P, and Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 81: 1-44, 2003. (Pubitemid 35436609)
55. González-Mariscal L Quiró s M, and Díaz- Coránguez M. ZO proteins and redox-dependent processes. Antioxid Redox Signal 15 1235-1253 2011.
56. Gustavsson C, Agardh E, Bengtsson B, and Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications 22: 309-316, 2008.
57. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002. (Pubitemid 34298608)
58. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, and Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 47: 5106-5115, 2006. (Pubitemid 46586418)
59. Hille R and Nishino T. Flavoprotein structure and mechanism. Xanthine oxidase and xanthine dehydrogenase. FASEB J 9: 995-1003, 1995.
60. Inkster ME, Cotter MA, and Cameron NE. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol 561: 63-71, 2007. (Pubitemid 46435845)
61. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, and Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-1945, 2000.
62. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, and Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 25: 67-82, 1981. (Pubitemid 11087436)
63. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, and Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59: 850-860, 2010.
64. John LJ, Fromm M, and Schulzke JD. Epithelial barriers in intestinal inflammation. Antioxid Redox Signal 15: 1255-1270, 2011.
65. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, and Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18: 1450-1452, 2004. (Pubitemid 39561611)
66. JoussenAM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, and Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16: 438-440, 2002.
67. Kanwar M, Chan PS, Kern TS, and Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: Possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci 48: 3805-3811, 2007. (Pubitemid 351261121)
68. Kato N, Yashima S, Suzuki T, Nakayama Y, and Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 17: 374-379, 2003. (Pubitemid 37315949)
69. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, and Kim CD. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51: 522-527, 2002. (Pubitemid 34764812)
70. Kowluru RA, Atasi L, and Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 47: 1594-1599, 2006. (Pubitemid 46780770)
71. Kowluru RA, Engerman RL, and Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. Curr Eye Res 21: 814-819, 2000. (Pubitemid 32099432)
72. Kowluru RA, Kowluru V, Xiong Y, and Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic Biol Med 41: 1191-1196, 2006. (Pubitemid 44466317)
73. Kowluru RA and Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53: 3233-3238, 2004. (Pubitemid 39564500)
74. Kowluru RA and Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: Effect of antioxidants. Invest Ophthalmol Vis Sci 45: 4161-4166, 2004. (Pubitemid 39411175)
75. Kowluru RA and Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 88: 1343-1347, 2004. (Pubitemid 39312984)
76. Lakshminarayanan S, Antonetti DA, Gardner TW, and Tarbell JM. Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: The role of NO. Invest Ophthalmol Vis Sci 41: 4256-4261, 2000.
77. Lassegue B and Clempus RE. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285: R277-297, 2003. (Pubitemid 36898897)
78. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, and Zhang SX. Inhibition of reactive oxygen species by lovastatin downregulates VEGF expression and ameliorates blood-retinal barrier breakdown in db/db mice: Role of NADPH oxidase Diabetes 59: 1528-1538, 2010.
79. Li JM and Shah AM. Endothelial cell superoxide generation: Regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-1030, 2004. (Pubitemid 39391043)
80. Lopez-Quintero SU, Ji XY, Antonetti DA, Tarbell JM. A three-pore model describes transport properties of bovine retinal endothelial cells in normal and elevated glucose. Invest Opthalmol Vis Sci 52: 1171-1180.
81. Lutty GA, McLeod DS, Merges C, Diggs A, and Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 114: 971-977, 1996. (Pubitemid 26271463)
82. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, and Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112: 1476-1482, 1994. (Pubitemid 24350514)
83. Misko TP, Highkin MK, Veenhuizen AW, Manning PT, Stern MK, Currie MG, and Salvemini D. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem 273: 15646-15653, 1998. (Pubitemid 28298180)
84. Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima E, Kato K, Kasuya Y, Yasuda Y, Kamiya H, and Hotta N. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 60: 1-9, 2003. (Pubitemid 36299247)
85. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, and Adamis AP. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96: 10836-10841, 1999. (Pubitemid 29442230)
86. Mohr S. Potential new strategies to prevent the development of diabetic retinopathy. Expert Opin Investig Drugs 13: 189-198, 2004. (Pubitemid 38351341)
87. Mohr S, Xi X, Tang J, and Kern TS. Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51: 1172-1179, 2002. (Pubitemid 34438365)
88. Moss SE, Klein R, and Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998-1003, 1998. (Pubitemid 28268322)
89. Murakami T, Felinski EA, and Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem 284: 21036-21046, 2009.
90. Nishikawa T, Edelstein D, and Brownlee M. The missing link: A single unifying mechanism for diabetic complications. Kidney Int Suppl 77: S26-30, 2000.
91. Nyengaard JR, Ido Y, Kilo C, and Williamson JR. Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. Diabetes 53: 2931-2938, 2004. (Pubitemid 39425919)
92. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, and Stevens MJ. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52: 864-871, 2003. (Pubitemid 36323597)
93. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, and Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134: 348-353, 2002.
94. Ogata N, Wang L, Jo N, Tombran-Tink J, Takahashi K, Mrazek D, and Matsumura M. Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury. Curr Eye Res 22: 245-252, 2001. (Pubitemid 32881412)
95. Ola MS, Berkich DA, Xu Y, King MT, Gardner TW, Simpson I, and LaNoue KF. Analysis of glucose metabolism in diabetic rat retinas. Am J Physiol Endocrinol Metab 290: E1057-1067, 2006. (Pubitemid 43847888)
96. Overgaard CE, Daugherty BL, Mitchell LA, and Koval M. Claudins: control of barrier function and regulation in response to oxidant stress. Antioxid Redox Signal 15: 1179-1193, 2011.
97. Platt DH, Bartoli M, El-Remessy AB, Al-Shabrawey M, Lemtalsi T, Fulton D, and Caldwell RB. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic Biol Med 39: 1353-1361, 2005. (Pubitemid 41540090)
98. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, and Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 126: 1740-1747, 2008.
99. Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H, Noda T, and Tsukita S. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 11: 4131-4142, 2000.
100. Sander B, Larsen M, Moldow B, and Lund-Andersen H. Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 42: 433-438, 2001. (Pubitemid 32121476)
101. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, and Stehouwer CD.Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes. The EURODIAB Prospective Complications Study. Diabetologia 48: 370-378, 2005. (Pubitemid 40543311)
102. Schrufer TL, Antonetti DA, Sonenberg N, Kimball SR, Gardner TW, and Jefferson LS. Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Muller cells in culture. Diabetes 59: 2107-2116, 2010.
103. Shen L, Su L and Turner JR. Mechanisms and functional implications of intestinal barrier defects. Dig Dis 27: 443-449, 2009.
104. Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, Matsumoto S, Utsumi H, and Nawata H. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med 37: 115-123, 2004. (Pubitemid 38746655)
105. Sundstrom JM, Tash BR, Murakami T, Flanagan JM, Bewley MC, Stanley BA, Gonsar KB, and Antonetti DA. Identification and analysis of occludin phosphosites: A combined mass spectrometry and bioinformatics approach. J Proteome Res 8: 808-817, 2009.
106. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, and Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196-5203, 2002. (Pubitemid 35033454)
107. Thornit DN, Vinten CM, Sander B, Lund-Andersen H, and la Cour M. Blood-retinal barrier glycerol permeability in diabetic macular edema and healthy eyes: Estimations from macular volume changes after peroral glycerol. Invest Ophthalmol Vis Sci 51: 2827-2834, 2009.
108. Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, Kilo C, and Williamson JR. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38: 1258-1270, 1989. (Pubitemid 19247421)
109. Tombran-Tink J, Chader GG, and Johnson LV. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 53: 411-414, 1991.
110. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH, and Williamson JR. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 36: 1675-1685, 1995.
111. Vincent JA and Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56: 224-230, 2007.
112. Warboys CM, Toh HB, and Fraser PA. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 50: 1319-1328, 2009.
113. Wild S, Roglic G, Green A, Sicree R, and King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004. (Pubitemid 38579764)
114. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, and Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993. (Pubitemid 23151571)
115. Winkler BS, Arnold MJ, Brassell MA, and Sliter DR. Glucose dependence of glycolysis, hexose monophosphate shunt activity, energy status, and the polyol pathway in retinas isolated from normal (nondiabetic) rats. Invest Ophthalmol Vis Sci 38: 62-71, 1997. (Pubitemid 27051525)
116. Xie L, Zhu X, Hu Y, Li T, Gao Y, Shi Y, and Tang S. Mitochondrial DNA oxidative damage triggering mitochondrial dysfunction and apoptosis in high glucose-induced HRECs. Invest Ophthalmol Vis Sci 49: 4203-4209, 2008.
117. Yamagishi S, Nakamura K, Matsui T, Sato T, and Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 66: 1019-1021, 2006. (Pubitemid 43207665)
118. Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamgishi S, Morito N, Nakano T, Ojima M, Shimohata H, Itoh K, Takahashi S, and Yamamoto M. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 13: 1159-1170, 2008.
119. Yoshida Y, Yamagishi S, Matsui T, Jinnouchi Y, Fukami K, Imaizumi T, and Yamakawa R. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 25: 678-686, 2009.
120. Zhang H. Scanning electron-microscopic study of corrosion casts on retinal and choroidal angioarchitecture in man and animals. Prog Ret Eye Res 13: 243-270, 1994. (Pubitemid 24086382)
121. Zheng Z, Chen H, Ke G, Fan Y, Zou H, Sun X, Gu Q, Xu X, and Ho PC. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: Involvement of a mitochondria-reactive oxygen species pathway. Diabetes 58: 954-964, 2009.
122. Zheng Z, Chen H, Zhao H, Liu K, Luo D, Chen Y, Yang X, Gu Q, and Xu X. Inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through a mitochondrial ROS pathway in vitro. Invest Ophthalmol Vis Sci 51: 64-71, 2010.
123. Zhou Q and Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 74: 818-826, 2010.